Form 4: Moderna President Stephen Hoge Executes RSU Vesting

Moderna President Stephen Hoge acquired shares through the vesting of restricted stock units and withheld shares for tax obligations.

Summary

• President Stephen Hoge acquired 1,437 shares of common stock on May 27, 2026, and 610 shares on May 28, 2026, via the vesting of restricted stock units (RSUs).
• A portion of these shares was withheld to satisfy tax obligations: 695 shares at $47.03 per share on May 27, and 295 shares at $47.61 per share on May 28.
• Following these transactions, the reporting person maintains a direct beneficial ownership of 1,479,054 shares of Moderna common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine administrative activity regarding executive equity compensation rather than a strategic shift.

Positives

• The transaction reflects the standard vesting of equity compensation, indicating continued alignment between executive interests and long-term shareholder value.

Negatives

• The filing indicates a routine reduction in share count due to tax withholding obligations associated with RSU vesting.

Risks

• No specific operational or financial risks are disclosed in this Form 4 filing.

Future Outlook

Not applicable; this is a routine disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related share withholding are standard practices for executive compensation in the biotechnology sector and do not typically signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction structure is consistent with standard executive compensation practices observed at large-cap pharmaceutical and biotech firms like Pfizer, Merck, and BioNTech.

Related Party Transactions

• The filing notes 4,116 shares held by Valhalla, LLC and 151,933 shares held by a trust for the benefit of the reporting person's spouse and children.

Stakeholder Impact

• Minimal impact on shareholders as these transactions are part of pre-existing compensation agreements.

Next Steps

• Future vesting of remaining restricted stock units as per the established quarterly schedule.

Key Dates

Keywords

Moderna, MRNA, Stephen Hoge, Insider Trading, Form 4, Equity Compensation, Biotech